ReviewCold Spring Harbor perspectives in medicine2018
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
Review in Cold Spring Harbor perspectives in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.Future oncology (London, England) · 2025Pooled it
- Transcriptomic analysis of castration, chemo-resistant and metastatic prostate cancer elucidates complex genetic crosstalk leading to disease progression.Functional & integrative genomics · 2021Pooled it
- Pooled it
- Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.Medicine · 2020Pooled it
- Drug repositioning in metastatic prostate cancer based on protein- protein interaction network: Computational and in vitro analysis.Biochemistry and biophysics reports · 2026Article
- Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States.Health policy OPEN · 2026Article
- 177Lu-vipivotide tetraxetan (PSMA-617) vs cabazitaxel in metastatic castration-resistant prostate cancer: a real-world analysis using the TriNetX database.International urology and nephrology · 2026Article
- Article
- Assessment of cytotoxic effects of Prunus Africana extracts on prostate cancer C4-2 cells in vitro.BMC complementary medicine and therapies · 2026Article
- ZNF711 promotes enzalutamide resistance through transcriptional and epigenetic modification of the androgen receptor signaling pathway.Cellular and molecular life sciences : CMLS · 2026Article
- In Vivo Prostate Cancer Modelling: From the Pre-Clinical to the Clinical Setting.Life (Basel, Switzerland) · 2026Review
- Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel.Case reports in urology · 2026Article
- Identification of interleukin-11 as a comorbid risk factor for prostate cancer and Alzheimer's disease using integrated bioinformatics and machine learning.Frontiers in immunology · 2026Article
- Piceatannol and Pumpkin Seed Oil Synergistically Promote Apoptosis of PC3 Prostate Cancer Cells via Intrinsic Mitochondrial Pathway.ACS omega · 2025Article
- Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.Nature communications · 2025Article
- Prostate-Specific Membrane Antigen (PSMA)-Directed Dendrimer-Camptothecin Conjugate for Targeted Treatment of Prostate Cancer.ACS applied nano materials · 2025Article
- Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison.Prostate cancer and prostatic diseases · 2025Article
- Article
- Transforming Prostate Cancer Care: Innovations in Diagnosis, Treatment, and Future Directions.International journal of molecular sciences · 2025Review
- Integrating multimodal data to predict the progression of hormone-sensitive prostate cancer.Clinical proteomics · 2025Article
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite many recent advances in the therapy for metastatic castration-resistant prostate cancer (mCRPC), the disease remains incurable, although men suffering from this disease are living considerably longer. In this review, we discuss the current treatment options available for this disease, such as taxane-based chemotherapy, the novel hormone therapies abiraterone and enzalutamide, and treatments such as radium-223 and sipuleucel-T. We also highlight the need for ongoing research in this field, because, despite numerous recent advances, the prognosis for mCRPC remains poor. Furthermore, as a growing body of evidence shows the increasing heterogeneity of the disease, and highlights the ongoing need for disease molecular stratification and validation/qualification of predictive biomarkers, we explore this burgeoning research space that is likely to transform how we treat this disease. We describe putative predictive biomarkers, including androgen receptor splice variants, phosphatase and tensin homolog (PTEN) loss, homologous recombination repair defects, including BRCA2 loss, and mismatch repair defects. The development of next-generation sequencing techniques and the routine biopsy of metastatic disease have driven significant advances in our understanding of the genomics of cancer, and are now poised to transform our treatment of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.